These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 2908364)
1. EGYT-2509 a novel neuroleptic agent without extrapyramidal and endocrine side effects. Gacsályi I; Petöcz L; Fekete MI; Bükkfálvi B; Görgenyi F; Arató M Pol J Pharmacol Pharm; 1988; 40(6):613-9. PubMed ID: 2908364 [TBL] [Abstract][Full Text] [Related]
2. Interactions of apomorphine and a novel neuroleptic dibenzodioxazocine derivative, as evidenced by changes of somato-autonomic reflexes and spontaneous sympathetic activity in cats. Dóda M J Pharm Pharmacol; 1989 Aug; 41(8):549-54. PubMed ID: 2571699 [TBL] [Abstract][Full Text] [Related]
3. Potentiation of cataleptogenic effects of neuroleptics by prostaglandins. Herman ZS; Słomińska-Zurek J; Kryk A; Kmieciak-Kołada K Pol J Pharmacol Pharm; 1978; 30(5):639-46. PubMed ID: 35782 [TBL] [Abstract][Full Text] [Related]
4. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184 [TBL] [Abstract][Full Text] [Related]
5. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent]. Ogren SO; Hall H; Köhler C; Magnusson O; Florvall L Arzneimittelforschung; 1985; 35(8):1227-31. PubMed ID: 2866774 [TBL] [Abstract][Full Text] [Related]
7. Differential reversal by scopolamine of effects of neuroleptics in rats. Relevance for evaluation of therapeutic and extrapyramidal side-effect potential. Arnt J; Christensen AV; Hyttel J Neuropharmacology; 1981 Dec; 20(12B):1331-4. PubMed ID: 6119645 [No Abstract] [Full Text] [Related]
8. Possible involvement of the dopaminergic system in the mode of action of the potential antidepressant trazium esilate. Gyertyán I; Petöcz L; Bajnógel J; Szücs Z; Hegedüs M; Gyüre K; Gacsályi I; Krizsán D; Fekete MI Arzneimittelforschung; 1989 Jul; 39(7):775-81. PubMed ID: 2551306 [TBL] [Abstract][Full Text] [Related]
9. Potential antipsychotic and extrapyramidal effects of (R,S)-3,4-dicarboxyphenylglycine [(R,S)-3,4-DCPG], a mixed AMPA antagonist/mGluR8 agonist. Ossowska K; Pietraszek M; Wardas J; Wolfarth S Pol J Pharmacol; 2004; 56(3):295-304. PubMed ID: 15215559 [TBL] [Abstract][Full Text] [Related]
10. Neuropsychopharmacological profile of remoxipride in comparison with clozapine. Skuza G; Rogóz Z; Wieczorek A Pol J Pharmacol; 1997; 49(1):5-15. PubMed ID: 9431546 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological study of [2-chloro-11-(2-dimethylaminoethoxy) dibenzo[b,f]thiepine] (zotepine), a new neuroleptic drug. Uchida S; Honda F; Otsuka M; Satoh Y; Mori J; Ono T; Hitomi M Arzneimittelforschung; 1979; 29(10):1588-94. PubMed ID: 42413 [TBL] [Abstract][Full Text] [Related]
12. Substituted ergolines: potential antipsychotics with unique profile. I. Psychopharmacological characterization. Groó D; Palosi A Pol J Pharmacol Pharm; 1988; 40(6):593-601. PubMed ID: 2908363 [TBL] [Abstract][Full Text] [Related]
13. [Neuroleptic-like activity of the tripeptide neurotensin analog GZR-123]. Guzevatykh LS; Ostrovskaia RU; Gudasheva TA; Zaĭtseva NI; Voronina TA Eksp Klin Farmakol; 2002; 65(1):3-6. PubMed ID: 12025780 [TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties. Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965 [TBL] [Abstract][Full Text] [Related]
15. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. Kapur S; Langlois X; Vinken P; Megens AA; De Coster R; Andrews JS J Pharmacol Exp Ther; 2002 Sep; 302(3):1129-34. PubMed ID: 12183672 [TBL] [Abstract][Full Text] [Related]
16. Central action of narcotic analgesics. I. Catalepsy and stereotypy in rats and narcotic analgesics. Malec D; Fidecka S; Langwiński R Pol J Pharmacol Pharm; 1977; 29(3):177-93. PubMed ID: 560683 [TBL] [Abstract][Full Text] [Related]
17. Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Lipska BK; Jaskiw GE; Braun AR; Weinberger DR Biol Psychiatry; 1995 Aug; 38(4):255-62. PubMed ID: 8547448 [TBL] [Abstract][Full Text] [Related]
18. Injection of apomorphine--a test to predict individual different dopaminergic sensitivity? Surmann A; Havemann-Reinecke U J Neural Transm Suppl; 1995; 45():143-55. PubMed ID: 8748620 [TBL] [Abstract][Full Text] [Related]
19. Central action of glaucine in rodents. Jagiełło-Wójtowicz E; Kleinrok Z; Jusiak L; Matuszek B; Daniłoś J; Chodakowska A Acta Pol Pharm; 1994; 51(2):179-84. PubMed ID: 7863789 [TBL] [Abstract][Full Text] [Related]
20. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents. Millan MJ; Brocco M; Rivet JM; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion JL; Dekeyne A J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]